Innoplexus, a Germany and India based DaaS (Data as a Service) startup has announced the closing of their Pre-Series A funding from HCS, a Germany-based Venture Capital Fund. With the capital raised, Innoplexus plans to file more patent applications, further develop their trademark platform, iPlexus, and invest in marketing.
Innoplexus helps Life Sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. It’s unique Data as a Service (DaaS) engine with real-time data and insights along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications help enterprises make better data-driven decisions.
Hans-Christian Semmler, managing shareholder of HCS, will join as Chairman of the supervisory board of Innoplexus. He started his career in investment banking eventually serving as the CFO of VosslohAG and then as the CEO of Haupt Pharma AG.
Speaking on the recent development Dr. Gunjan Bhardwaj, Co-Founder and CEOsaid, “We envision to fundamentally transform the Data as a Service landscape for Life Sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data."Gaurav Tripathi, Co-Founder and India CEO, further added saying, "We are working in cutting edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property."
Within their investment strategy, HCS Beteiligungsgesellschaft GmbH strongly focuses on organisations that are distinguished by their technological expertise and their market potential. Innoplexus clients are Fortune 500 companies including some of the world’s largest pharmaceutical companies. The startup employs more than 100 highly qualified data Science and software development experts in India and Germany.
Innoplexus helps Life Sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. It’s unique Data as a Service (DaaS) engine with real-time data and insights along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications help enterprises make better data-driven decisions.
Hans-Christian Semmler, managing shareholder of HCS, will join as Chairman of the supervisory board of Innoplexus. He started his career in investment banking eventually serving as the CFO of VosslohAG and then as the CEO of Haupt Pharma AG.
Speaking on the recent development Dr. Gunjan Bhardwaj, Co-Founder and CEOsaid, “We envision to fundamentally transform the Data as a Service landscape for Life Sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data."Gaurav Tripathi, Co-Founder and India CEO, further added saying, "We are working in cutting edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property."
Within their investment strategy, HCS Beteiligungsgesellschaft GmbH strongly focuses on organisations that are distinguished by their technological expertise and their market potential. Innoplexus clients are Fortune 500 companies including some of the world’s largest pharmaceutical companies. The startup employs more than 100 highly qualified data Science and software development experts in India and Germany.
Advertisements